Perhaps another 'press release' that couldn't answer any of your questions...
20 September 2017
I would like to take some time to update you on the advances we have made at MGC Pharmaceuticals in the past months, covering both our activities and market position. MGC Pharmaceuticals is currently evolving from its position as a medical cannabis company, to become a pharmaceutical company with a self-contained value chain (spanning growing operations through to research and drug development) for harnessing phytocannabinoids as Active Pharmaceutical Ingredients (API) in medicinal products.
Our value chain for developing phytocannabinoid API containing medicinal cannabis products is a significant point of difference for MGC Pharmaceuticals, as it positions the Company ahead of our potential competitors in this emerging sector. Additionally, it focuses our core operations on our vision to provide medications, globally, to patients in need.
Our progress towards this key goal is already very strong. In Europe, MGC Pharmaceuticals is poised to commence its Phase 2 Clinical study for Epilepsy pending final regulatory approval in Slovenia. The Company has also recently completed the construction and testing of a cutting-edge cleanroom within our European Extraction facility, and is now awaiting Good Manufacturing Practice certification for the facility to be able to produce API materials. These are important steps on the way to supporting the Company’s product line, which currently includes our three key product formulation groups:
• MGCND00EP1® for Neurological Disorders
• MGCON00CA1® for Oncology treatment and side effects
• MGCAU00SD1® for Autoimmune treatments in inflammatory cases
MGC Pharmaceuticals plans to register, prescribe and eventually provide these medicines to patients.
